Intuitive Surgical, Inc.
ISRGHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeIntuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company carries a $125.45B market cap, placing it firmly in the large-cap category. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
Market Cap
$125.45B
Beta
1.47
P/E (TTM)
40.11
P/E (Fwd)
29.01
EPS (TTM)
$8.73
EPS (Fwd)
$12.07
ROE
17.4%
ROA
10.5%
Cash
$5.22B
Total Debt
$0
Free CF
$2.62B
52W Change
-18.5%
Annual Financials
Cash vs Debt
Where ISRG stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ISRG finished 15.16% below its 150-day moving average ($435.23) and 20.86% below its 200-day moving average ($466.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ISRG overbought or oversold?
At the September 2, 2026 close, ISRG's RSI(14) was 28.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intuitive Surgical, Inc. reports $5.22B in cash and $0 in total debt. Free cash flow comes in at $2.62B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 17.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has grown from $6.22B (2022) to $10.06B (2025), reflecting a 62% increase over the period.
As with any equity investment, ISRG carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Intuitive Surgical, Inc.'s trajectory.